一种毒素的驯化指南——用绿脓杆菌外毒素 A 构建的重组免疫毒素用于癌症治疗。
A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer.
机构信息
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4264, USA.
出版信息
FEBS J. 2011 Dec;278(23):4683-700. doi: 10.1111/j.1742-4658.2011.08182.x. Epub 2011 Jun 2.
Abstract
Pseudomonas exotoxin A (PE) is a highly toxic protein secreted by the opportunistic pathogen Pseudomonas aeruginosa. The modular structure and corresponding mechanism of action of PE make it amenable to extensive modifications that can redirect its potent cytotoxicity from disease to a therapeutic function. In combination with a variety of artificial targeting elements, such as receptor ligands and antibody fragments, PE becomes a selective agent for the elimination of specific cell populations. This review summarizes our current understanding of PE, its intoxication pathway, and the ongoing efforts to convert this toxin into a treatment for cancer.
摘要
绿脓杆菌外毒素 A（PE）是一种由机会性病原体铜绿假单胞菌分泌的高度毒性蛋白。PE 的模块化结构和相应的作用机制使其易于进行广泛的修饰，从而将其强大的细胞毒性从疾病转移到治疗功能上。与各种人工靶向元件（如受体配体和抗体片段）结合使用时，PE 成为消除特定细胞群体的选择性试剂。本综述总结了我们目前对 PE 的认识，包括其毒素作用途径以及将这种毒素转化为癌症治疗方法的研究进展。
相似文献
1
A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer.
FEBS J. 2011 Dec;278(23):4683-700. doi: 10.1111/j.1742-4658.2011.08182.x. Epub 2011 Jun 2.
2
Designing the furin-cleavable linker in recombinant immunotoxins based on Pseudomonas exotoxin A.
Bioconjug Chem. 2015 Jun 17;26(6):1120-8. doi: 10.1021/acs.bioconjchem.5b00190. Epub 2015 Jun 3.
3
Mechanisms of Resistance to Immunotoxins Containing Exotoxin A in Cancer Therapy.
Biomolecules. 2020 Jun 30;10(7):979. doi: 10.3390/biom10070979.
4
Immunotoxins containing Pseudomonas exotoxin A: a short history.
Cancer Immunol Immunother. 2003 May;52(5):338-41. doi: 10.1007/s00262-002-0353-8. Epub 2003 Mar 6.
5
Modular Conjugation of a Potent Anti-HER2 Immunotoxin Using Coassociating Peptides.
Bioconjug Chem. 2020 Oct 21;31(10):2421-2430. doi: 10.1021/acs.bioconjchem.0c00482. Epub 2020 Sep 30.
6
Immunogenicity of therapeutic recombinant immunotoxins.
Immunol Rev. 2016 Mar;270(1):152-64. doi: 10.1111/imr.12390.
7
Is Pseudomonas aeruginosa exotoxin A a good carrier protein for conjugate vaccines?
Hum Vaccin. 2007 Mar-Apr;3(2):39-40; author reply 41. doi: 10.4161/hv.3.2.3715. Epub 2007 Mar 8.
8
Higher cytotoxicity of divalent antibody-toxins than monovalent antibody-toxins.
Biochem Biophys Res Commun. 2009 Apr 24;382(1):15-20. doi: 10.1016/j.bbrc.2009.02.091. Epub 2009 Feb 24.
9
Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A.
Toxins (Basel). 2016 Jul 25;8(8):217. doi: 10.3390/toxins8080217.
10
Therapeutic efficacy of Cintredekin Besudotox (IL13-PE38QQR) in murine lung fibrosis is unaffected by immunity to Pseudomonas aeruginosa exotoxin A.
PLoS One. 2010 Jan 15;5(1):e8721. doi: 10.1371/journal.pone.0008721.
引用本文的文献
1
Intracellular trafficking of furin enhances cellular intoxication by recombinant immunotoxins based on Pseudomonas exotoxin A.
Biol Open. 2025 Jun 15;14(6). doi: 10.1242/bio.061792. Epub 2025 Jun 20.
2
Assessment of the Effects of Single-Domain Anti-Idiotypic Distribution Enhancers on the Disposition of Trastuzumab and on the Efficacy of a PE24-Trastuzumab Immunotoxin.
Cancers (Basel). 2025 Apr 27;17(9):1468. doi: 10.3390/cancers17091468.
3
Mesothelin as a Signal Pathways and Epigenetic Target in Cancer Therapy.
Cancers (Basel). 2025 Mar 26;17(7):1118. doi: 10.3390/cancers17071118.
4
exotoxin A as a novel allergen induced Non-T2 inflammation in a murine model of steroid-insensitive asthma.
Heliyon. 2024 Sep 5;10(18):e37512. doi: 10.1016/j.heliyon.2024.e37512. eCollection 2024 Sep 30.
5
Advances in immunotoxin engineering: precision therapeutic strategies in modern oncology.
Med Oncol. 2024 Sep 4;41(10):239. doi: 10.1007/s12032-024-02478-3.
6
Pierisin, Cytotoxic and Apoptosis-Inducing DNA ADP-Ribosylating Protein in Cabbage Butterfly.
Toxins (Basel). 2024 Jun 14;16(6):270. doi: 10.3390/toxins16060270.
7
Hosts and Heterologous Expression Strategies of Recombinant Toxins for Therapeutic Purposes.
Toxins (Basel). 2023 Dec 13;15(12):699. doi: 10.3390/toxins15120699.
8
Novel Anti-Mesothelin Nanobodies and Recombinant Immunotoxins with Exotoxin Catalytic Domain for Cancer Therapeutics.
Mol Cells. 2023 Dec 31;46(12):764-777. doi: 10.14348/molcells.2023.0155. Epub 2023 Dec 1.
9
A pH-Responsive Virus-Like Particle as a Protein Cage for a Targeted Delivery.
Adv Healthc Mater. 2024 Feb;13(4):e2302656. doi: 10.1002/adhm.202302656. Epub 2023 Nov 27.
10
Potent and selective eradication of tumor cells by an EpCAM-targeted Ras-degrading enzyme.
Mol Ther Oncolytics. 2023 Jun 27;30:16-26. doi: 10.1016/j.omto.2023.06.002. eCollection 2023 Sep 21.
本文引用的文献
1
Toxin-based therapeutic approaches.
Toxins (Basel). 2010 Nov;2(11):2519-83. doi: 10.3390/toxins2112519. Epub 2010 Oct 28.
2
Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes.
Proc Natl Acad Sci U S A. 2011 Apr 5;108(14):5742-7. doi: 10.1073/pnas.1102746108. Epub 2011 Mar 21.
3
A dominant-negative approach that prevents diphthamide formation confers resistance to Pseudomonas exotoxin A and diphtheria toxin.
PLoS One. 2010 Dec 23;5(12):e15753. doi: 10.1371/journal.pone.0015753.
4
Endogenous ADP-ribosylation of elongation factor-2 by interleukin-1β.
Mol Cell Biochem. 2011 Feb;348(1-2):125-8. doi: 10.1007/s11010-010-0646-8. Epub 2010 Nov 19.
5
Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas.
Int J Cancer. 2011 Jul 1;129(1):111-21. doi: 10.1002/ijc.25645. Epub 2010 Nov 3.
6
Targeted therapies: Denileukin diftitox--a step towards a 'magic bullet' for CTCL.
Nat Rev Clin Oncol. 2010 Aug;7(8):430-2. doi: 10.1038/nrclinonc.2010.105.
7
Pseudomonas exotoxin kills Drosophila S2 cells via apoptosis.
Toxicon. 2010 Nov;56(6):1025-34. doi: 10.1016/j.toxicon.2010.07.007. Epub 2010 Jul 24.
8
ABT-737 overcomes resistance to immunotoxin-mediated apoptosis and enhances the delivery of pseudomonas exotoxin-based proteins to the cell cytosol.
Mol Cancer Ther. 2010 Jul;9(7):2007-15. doi: 10.1158/1535-7163.MCT-10-0257. Epub 2010 Jun 29.
9
Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs.
PLoS Pathog. 2010 Jun 10;6(6):e1000803. doi: 10.1371/journal.ppat.1000803.
10
Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia.
Br J Haematol. 2010 Aug;150(3):352-8. doi: 10.1111/j.1365-2141.2010.08251.x. Epub 2010 Jun 7.
Zotero 插件